article
Synthetic promoters enhance gene therapy precision
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
List view / Grid view
Biotherapeutics
article
Next-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
article
Abelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
article
Empowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
news
Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
news
Bio-Rad introduces mixed-mode resin for biomolecule purification
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
article
Toxicology transformed: Why accuracy now leads the way
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
news
Blood-brain barrier breakthrough for ALS and Alzheimer’s disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
article
Transforming cancer treatment for greatest impact
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
article
Key considerations before commencing cell line development
Cell line development (CLD) is a critical, early step when entering the development phase of a biotherapeutic. Access to specialist skills and experience, either in-house or remotely, and to multiple technologies and equipment can prove invaluable for the timely and successful completion of this stage. Here, Dr Alison Porter addresses…
whitepaper
Infographic: Targeted protein degradation
In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach and the key points you need to consider when designing your protein degraders.
whitepaper
Product hub: Why automation is outpacing traditional methods for single-cell cloning
Learn more about the CellCelector platform and its unique nanowell plate technology, which is key to the high cell integrity and outgrowth rates after picking.
video
Webinar: Plasmid platform facilitates transition to clinic
Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
news
Vitamin C improves immunogenic properties of dendritic cells, study shows
Spanish researchers have discovered that vitamin C may hold the key to improving the efficacy of dendritic cell-derived anticancer therapies.
news
FDA clears Cellenkos IND application for potential ALS treatment
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
